No increased heart failure risk is reported with DPP-4 inhibitors

The risk of heart failure is no higher in patients taking the dipeptidyl peptidase-4 inhibitors (DPP-4) saxagliptin or sitagliptin than in those taking other drugs commonly prescribed for type 2 diabetes, researchers have found.1